A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

NCT03730662 · Completed

Last updated 2026-05-28

This study is testing the effects of a once-weekly injection called tirzepatide compared to a daily insulin injection called insulin glargine in adults with type 2 diabetes who also have an increased risk of heart disease.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 2,002 people

Who can join Ages 18+ · all sexes

Timeline Started 2018-11 · est. completion 2021-04

Where 216 sites · Argentina, Australia, Brazil, Canada, Greece, Israel, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan, United States

What this study is testing ClinicalTrials.gov NCT03730662 ↗

Description as written by the study sponsor.

The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC.
Insulin Glargine Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03730662 ↗